Literature DB >> 7752320

The contemporary role of extra-anatomical surgical renal revascularization in patients with atherosclerotic renal artery disease.

A Fergany1, P Kolettis, A C Novick.   

Abstract

We delineate the current role of extra-anatomical revascularization techniques in the treatment of patients with atherosclerotic renal artery stenosis. There are 2 components to this study. In part 1 all abdominal aortograms performed between 1989 and 1993 were reviewed to document the presence of significant abdominal aortic and visceral arterial atherosclerosis in patients with atherosclerotic renal artery stenosis. A total of 254 patients with atherosclerotic renal artery stenosis was identified. Among 44 patients with severe unilateral disease the incidence of significant abdominal aortic atherosclerosis was 75%. The incidence of significant (greater than 50%) stenosis of the celiac, right common iliac and left common iliac arteries was 52%, 32% and 27%, respectively. In 129 patients with severe atherosclerotic renal artery stenosis bilaterally or in a solitary kidney the incidence of significant abdominal aortic atherosclerosis was 81%, and the incidence of significant (greater than 50%) stenosis of the celiac, right common iliac and left common iliac arteries was 59%, 57% and 59%, respectively. These data indicate that hepatorenal, splenorenal and iliorenal bypass cannot be performed in many patients with atherosclerotic renal artery stenosis due to significant disease involving the donor vessels for these operations. In part 2, all patients undergoing surgical renal revascularization with an extra-anatomical bypass operation between 1980 and 1992 were reviewed. A total of 175 operations was done in 171 patients, including hepatorenal bypass in 59, splenorenal bypass in 54, iliorenal bypass in 37, thoracic aortorenal bypass in 23, renal autotransplantation in 1 and superior mesentero-renal bypass in 1. There were 5 operative deaths (2.9%) and 7 cases of postoperative graft thrombosis (4%). All patients with poorly controlled hypertension were cured or improved postoperatively. Among patients with ischemic nephropathy, postoperative renal function improved in 35%, remained stable in 47% and deteriorated in 18%. Extra-anatomical techniques remain an important component of the surgical armamentarium for atherosclerotic renal artery stenosis. Thoracic aortorenal bypass is a useful new approach in patients with significant celiac and iliac occlusive disease.

Entities:  

Mesh:

Year:  1995        PMID: 7752320

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Outcome of renal artery reconstruction: analysis of 687 procedures.

Authors:  R C Darling; P B Kreienberg; B B Chang; P S Paty; W E Lloyd; R P Leather; D M Shah
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

Review 2.  Atherosclerotic renal artery stenosis: from diagnosis to treatment.

Authors:  P Carmichael; A R Carmichael
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

Review 3.  Troubleshooting Complex Vascular Cases in the Kidney Transplant Recipient: Vascular Anomalies, Challenging Vessel Diseases, and Procedural Disasters.

Authors:  Vital Hevia; Victoria Gómez; Manuel Hevia; Javier Lorca; Marta Santiago; Ana Dominguez; Sara Álvarez; Víctor Díez; Cristina Gordaliza; Francisco Javier Burgos
Journal:  Curr Urol Rep       Date:  2020-02-04       Impact factor: 3.092

4.  Treatment of Hostile Proximal Necks During Endovascular Aneurysm Repair.

Authors:  Tulio Pinho Navarro; Rodrigo de Castro Bernardes; Ricardo Jayme Procopio; Jose Oyama Leite; Alan Dardik
Journal:  Aorta (Stamford)       Date:  2014-02-01

5.  Medical Grand Rounds: refractory hypertension and renal insufficiency in a patient with renal artery stenosis.

Authors:  S J Huot; L M Scoutt; G H Meier
Journal:  Yale J Biol Med       Date:  1996 Sep-Oct

6.  Renal artery stenosis.

Authors:  Thomas Zeller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.